Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2016
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 86 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser
Targeting Nociceptors in Hidradenitis Suppurativa
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
Who cites it
86 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Australasian hidradenitis suppurativa management guidelines.The Australasian journal of dermatology · 2025Guideline
- Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.International journal of molecular sciences · 2020Pooled it
- Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Pooled it
- Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.JAMA dermatology · 2021Trial
- Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.The Journal of dermatology · 2021Trial
- Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.The Journal of dermatology · 2019Trial
- Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.Clinical pharmacokinetics · 2017Trial
- Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).Dermatology and therapy · 2026Article
- Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data.Medicina (Kaunas, Lithuania) · 2026Review
- Efficacy of Biologics for Hidradenitis Suppurativa: A Network Meta Analysis and Meta Regression for Baseline Disease Severity.The Australasian journal of dermatology · 2026Review
- Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Foreign body granuloma following leech therapy in hidradenitis suppurativa: A case complicated by lymphedema.Dermatology online journal · 2026Article
- Management of Hidradenitis Suppurativa in the United Arab Emirates (UAE): A Consensus Statement from the Emirates Dermatology Society.Dermatology and therapy · 2026Review
- Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study.Journal of inflammation research · 2026Article
- Secukinumab Efficacy Predictors in Korean Hidradenitis Suppurativa: A 48-Week Clinical Trial Analysis.Dermatology practical & conceptual · 2025Article
- Targeted Biologic Therapies for Hidradenitis Suppurativa.International journal of molecular sciences · 2025Review
- Safety and efficacy of biologics in patients with Down syndrome and hidradenitis suppurativa: a retrospective cohort study.Clinical and experimental dermatology · 2025Article
- Deep learning-based ranking method for subgroup and predictive biomarker identification in patients.Communications medicine · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDetermining treatment response for patients with hidradenitis suppurativa (HS) can be challenging due to limitations of current disease activity evaluations.
objectiveEvaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) and its utility as an outcome measure.
methodsPatients with baseline total abscess and inflammatory nodule count (AN count) of at least three and draining fistula count of 20 or fewer comprised the post hoc subpopulation analysed. HiSCR (at least a 50% reduction in total AN count, with no increase in abscess count, and no increase in draining fistula count relative to baseline) and HS-PGA Response [Hidradenitis Suppurativa-Physician's Global Assessment score of clear, minimal, or mild, with at least a 2-grade improvement from baseline] were used to evaluate patient response after adalimumab treatment weekly, every other week, or placebo (1 : 1 : 1).
resultsThe subpopulation included 132 (85.7%) patients; 70.5% women and 73.5% white. At week 16, HiSCR was achieved by 54.5% receiving weekly adalimumab, 33.3% every other week, and 25.6% placebo and HS-PGA Response was achieved by 20.5% receiving weekly adalimumab, 6.7% every other week and 2.3% placebo.
conclusionHiSCR was more responsive to change than HS-PGA Response in this subpopulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.